FSHR
ENSG00000170820
Target class
GPCR
Chromosome
2
Approved drugs
7
Clinical candidates (approved and in development)
7
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- FSHR
- Gene name
- Follicle stimulating hormone receptor
- Gene symbol
- FSHR
- Previous gene symbols
- ODG1
- Protein name
- Follicle-stimulating hormone receptor (FSH-R) (Follitropin receptor)
- FSHRO
- LGR1
- Gene biotype
- Protein coding
- Gene family
- Glycoprotein hormone receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 3.08
- Tissue specificity (Gini)
- 0.931
- Tissue specificity (tau)
- 0.991
- KEGG gene identifiers
- hsa:2492
- Protein interaction confidence
- 0.856577
- Protein interaction partners
- 26
- R-HSA-375281
- R-HSA-418555
- End position
- 49154527
- Start position
- 48962157
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 11847099
- PubMed 24692546
- Tissue specificity (tau)
- 0.99075
- Expression inequality (Gini)
- 0.930646
Expression in transcripts per million
- Testis
- 3.08
- Ovary
- 0.82
- Fallopian Tube
- 0.08
- Heart - Atrial Appendage
- 0.08
- Artery - Coronary
- 0.07
Expression in transcripts per million
- Testis3.08
- Ovary0.82
- Fallopian Tube0.08
- Heart - Atrial Appendage0.08
- Artery - Coronary0.07
- Esophagus - Gastroesophageal Junction0.06
- Brain - Frontal Cortex (BA9)0.05
- Esophagus - Muscularis0.05
- Colon - Sigmoid0.05
- Brain - Cortex0.04
- Bladder0.03
- Uterus0.02
- Nerve - Tibial0.02
- Heart - Left Ventricle0.02
- Artery - Aorta0.02
- Adipose - Visceral (Omentum)0.02
- Brain - Hypothalamus0.02
- Lung0.01
- Esophagus - Mucosa0.01
- Colon - Transverse0.01
- Brain - Cerebellum0.01
- Cervix - Ectocervix0.01
- Cervix - Endocervix0.01
- Kidney - Cortex0
- Liver0
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007283
- GO:0007292
- GO:0008406
- GO:0008584
- GO:0008585
- GO:0042699
- GO:0051897
- GO:0070374
- GO:0071372
- GO:0005886
- GO:0016020
- GO:0043235
- GO:0004963
- GO:0005515
Related records
Trials (313)
- 150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial
- 225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
- A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age
- A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment
- A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
- A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)
- A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)
- A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
- A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®
- A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
- A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α
- A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China
- A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve
- A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART
- A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women
- A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
- A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa
- A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility
- A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Drugs (7)
- Corifollitropin alfa Follicle stimulating hormone receptor agonist
- Follitropin Follicle stimulating hormone receptor agonist
- Follitropin alfa Follicle stimulating hormone receptor agonist
- Follitropin beta Follicle stimulating hormone receptor agonist
- Follitropin delta Follicle stimulating hormone receptor agonist
- Menotropins Follicle stimulating hormone receptor agonist
- Urofollitropin Follicle stimulating hormone receptor agonist